Advances in polymer nanomaterials targeting cGAS-STING pathway for enhanced cancer immunotherapy

Cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING) pathway has been recognized as a promising target for cancer immunotherapy. Although various STING agonists have been developed, their clinical applications are still severely impeded by various issues, such as non-specific accumulation, adverse effects, rapid clearance, etc. In recent years, the emergence of nanomaterials has profoundly revolutionized STING agonists delivery, which promote tumor-targeted delivery, boost the immunotherapeutic effects and reduce systemic toxicity of STING agonists. In particular, polymer nanomaterials possess inherent advantages including controllable structure, tunable function and degradability. These properties afford them the capacity to serve as delivery vehicles for small-molecule STING agonists. Furthermore, the superior characteristics of polymer nanomaterials can enable their utilization as a novel STING agonist to stimulate anti-tumor immunity. In this review, the molecular mechanisms of cGAS-STING pathway activation are discussed. The recent development of small-molecules STING agonists is described. Then polymer nanomaterials are discussed as carriers for STING agonists in cancer immunotherapy, including polymersomes, polymer micelles, polymer capsules, and polymer nanogels. Additionally, polymer nanomaterials are identified as a novel class of STING agonists for efficient cancer immunotherapy, encompassing both polymer materials and polymer-STING agonists conjugates. The review also presents the combination of polymer-based cGAS-STING immunotherapy with chemotherapy, radiotherapy, phototherapy (both photodynamic and photothermal), chemodynamic therapy, and other therapeutic strategies. Furthermore, the discussion highlights recent advancements targeting the cGAS-STING pathway in clinically approved polymer nanomaterials and corresponding potent innovations. Finally, the potential challenges and perspectives of polymer nanomaterials for activating cGAS-STING pathway are outlined, emphasizing the critical scientific issue and hoping to offer guidance for their clinical translation.

Photo-generating Type-I ROS and aryl radicals by mitochondrial-targeting oxime-ester photogenerator for pyroptosis-mediated anti-hypoxia photoimmunotherapy

Pyroptosis is an inflammatory form of programmed cell death with great potential in cancer immunotherapies. Photodynamic therapy (PDT) represents a promising treatment modality to trigger pyroptosis. However, the hypoxic microenvironment inside the tumors often induces limited therapeutic efficacy. Herein, in this work, the first type of mitochondrial-targeting oxime-ester photogenerator (T-Oximer) was constructed to boost type-I ROS/aryl free radicals which could induce DNA damage by DNA cleaving and facilitate high-efficiency pyroptosis-mediated photoimmunotherapy. Detailed mechanism investigations revealed that T-Oximer could produce aryl free radicals via photolysis reaction and generate type-I ROS (O2 •- and •OH) based on the type-I electron transfer process. Meanwhile, T-Oximer could accumulate in the mitochondria, boost mitochondrial radicals, and damage mitochondria in hypoxic tumor cells. Of peculiar interest, T-Oixmer could bind with DNA and cleave DNA to induce DNA damage. Combined mitochondrial damage with DNA cleavage, T-Oximer can initiate pyroptosis, activate the ICD effect, and trigger robust systemic antitumor immunity for efficient tumor regression and metastasis suppression. Our finding provides a new strategy for constructing oxygen-independent photogenerator for high-efficiency pyroptosis-mediated anti-hypoxia photoimmunotherapy.

Emerging synergistic strategies for enhanced antibacterial sonodynamic therapy: Advances and prospects

Antibacterial therapy has been extensively applied in medical field to alleviate the severity and mortality of infection. However, it still exists some issues such as drug side effects, limited efficacy and bacterial resistance. Among the alternative therapies, antibacterial sonodynamic therapy (aSDT) has been explored as a promising approach to tackle those crises. It is meaningful to investigate superior strategy to augment the therapeutic efficacy of aSDT. This review summarizes the potential aSDT-based antibacterial mechanisms and comprehensively discusses the prevailing synergistic strategies, such as nanomaterials-based aSDT antibacterial strategy, aSDT + strategy with physical, chemical and biological methods. Moreover, we also reviewed the medical applications of aSDT strategies. Finally, the perspectives on the current challenges that need be resolved in aSDT are proposed. We expect that this review could provide robust support to expedite the clinical applications of aSDT.

A Nanotherapeutic Agent for Synergistic Tumor Therapy: Co-Activation of Photochemical-Biological Effects

Single-mode photodynamic therapy (PDT) based on photochemical reactions is limited by the tumor microenvironment, which reduces the ablation efficiency for solid tumors. Making it vital to seek ways to improve the tumor therapeutic effect. Based on this, we propose a dual-mode intelligent nanotherapeutic system (HAP@BMPns) based on photochemical-biological effects. HAP@BMPns is composed of an acid-responsive high-calcium biomimetic nanomaterial (HAP) and photosensitizer (BMP), which can spontaneously activate photochemical (Type-I PDT) and biological effects for synergistic cancer therapy. HAP@BMPns breaks down upon entering tumor cells under acidic conditions, releasing a large amount of Ca2+ and BMP. Triggering intracellular Ca2+ overload, which induces mitochondrial damage, leading to apoptosis. Synchronously, Type-I PDT of BMP under two-photon (800 nm) laser irradiation becomes activated, resulting in enhanced destruction of tumor cells by the photochemical effect. Cell studies have indicated that HAP@BMPns (41.6 μg/mL) exhibits a strong inhibitory efficiency on tumor cells growth, with low (22.4 %) survival rate. However, the individual components, i. e. BMP (5.0 μM) and HAP (41.6 μg/mL) display low inhibitory efficiency with high survival rates (55.9 % and 63.0 % respectively). Therefore, this dual-mode synergistic treatment strategy using acid-triggered photochemical-biological effects significantly enhances the ablation of solid tumors, realizing the synergistic effect. We hope that this design strategy can provide guidance for the design and development of a tumor therapeutic platform.

Lactate-depleted pillar[5]arene-based chiral supramolecular nanovesicles for L-glucose-mediated tumor-specific chemodynamic- and photodynamic-synergistic therapy

The distinct interactions of D/L-glucose with cells and biological systems have garnered significant attention. However, the impact of chiral glucose-modified nanomaterials on cancer diagnosis and treatment remains largely unexplored. Here, based on the host-guest interaction between D-/L-glucose-modified pillar[5]arene (D-/L-CP5) serving as the host molecule and Fe-porphyrin derivatives (FeTPPNHC) acting as the guest, an acid-responsive chiral supramolecular vesicle was constructed for transporting lactate oxidases (LOx) (denoted as LOx@D-/L-CP5⊃FeTPPNHC), aiming to enhance chirality-mediated tumor-specific cascade chemodynamic therapy (CDT) and photodynamic therapy (PDT) through the depletion of lactic acid (LA). Surprisingly, the L-glucose-mediated chiral vesicles exhibit remarkable chirality recognition and lactate depletion capabilities, which were higher than the D-glucose-mediated chiral vesicles. Once internalized by cancer cells, L-supramolecular nanomicelles can directly consume LA to generate a considerable amount of H2O2, which can then be converted into ˙OH and 1O2. In vitro and in vivo studies demonstrate the high tumor specificity and therapeutic efficacy of LOx@LCP5⊃FeTPPNHC. The findings suggest that chiral glucose-modified nanomaterials hold great potential in targeted cancer treatment, paving the way for the development of innovative cancer therapeutics based on their unique interactions with biological systems.

A Lanthanide Nanoparticle-Aggregation-Induced Emission Photosensitizer Complex System Drives Coupled Triplet Energy Transfer for Enhanced Radio-Photodynamic Therapy

Cerenkov light (CL), utilized as an internal excitation source for photodynamic therapy (PDT), addresses the limitations of laser penetration and has substantial potential for seamlessly integrating clinical radiotheranostics with phototheranostics. Nevertheless, the effectiveness of CL-mediated PDT is significantly hindered by challenges, such as the low intensity of CL and inadequate energy transfer between the CL donor and photosensitizers (PSs). In this study, a novel approach is introduced for enhanced radionuclide-activated radio-photodynamic therapy utilizing a hybrid nanoparticle system composed of lanthanide nanoparticles and an aggregation-induced emission photosensitizer (AIE PS), designated LnNP-TQ NPs. This system enables lanthanide nanoparticles to optimize the decay energy of radionuclides, effectively sensitizing the AIE PS through triplet energy transfer (TET)-mediated processes with an efficiency approaching 100%. When activated by the clinical radionuclide 18F for positron emission tomography imaging, the LnNP-TQ NPs substantially inhibited tumor growth via effective singlet oxygen (1O2) generation. This strategy, which optimally harnesses radionuclide energy and achieves efficient energy transfer, offers a promising pathway for enhancing radiotherapy-phototherapy efficacy in tumor treatment.

A Hypoxia-Triggered Bioreduction of Hydrophilic Type I Photosensitizer for Switchable In Vivo Photoacoustic Imaging and High-Specificity Cancer Phototherapy

Considering that hypoxia is strongly connected with tumor proliferation, metastasis, invasion, and drug resistance, it is of significant implication for alleviating the effects of hypoxia in tumor treatment. The negligible oxygen-dependent nature of type I photosensitizers (PSs) has made them appropriate candidates for the treatment of hypoxic tumors. However, the lack of effective molecular design approaches, the phototoxicity of PSs to normal tissue before and after treatment, and the drawbacks of poor hydrophilicity severely hinder the development of PSs in hypoxic tumor therapy. Thus, developing a hydrophilic PS with good hypoxia resistance and minimal side effects is an urgent but challenging problem. Herein, we present a nanotheranostic (NanoPcN8O) based on the self-assembly of a hydrophilic phthalocyanine derivative (PcN8O), a hypoxia-responsive bioreductive phototherapeutic agent suitable for activatable photoacoustic (PA) imaging and tumor therapy. Hypoxic regions in various tumors exhibit strong reductive capability, and only in such conditions did NanoPcN8O feature multiple N-oxide groups that could be bioreduced to yield the product NanoPcN8 with abundant electron-rich tertiary amine groups, which switches on the type I photodynamic and photothermal effects, facilitating the generation of type I reactive oxygen species (ROS) and heat. Better still, NanoPcN8O achieved hypoxia-induced selective PA imaging in a preclinical model. Based on these merits, the hypoxia-induced switchable type I photodynamic therapy (PDT) and photothermal therapy (PTT) strategies demonstrated remarkable phototherapeutic efficiency with high biosafety. This delicate design is anticipated to offer a novel and safe strategy to overcome hypoxia resistance in phototherapeutics.

A Mo-doped carbon dot nanozyme for enhanced phototherapy in vitro

Cancer is a leading cause of death globally, and traditional treatment methods often come with non-negligible toxic side effects in its treatment, threatening patients' quality of life. Thus, developing novel, efficient, low-toxicity cancer treatment strategies is crucial. Nanozymes, as a class of powerful nanomaterials, can subtly mimic the catalytic activity of natural enzymes, making them a formidable alternative. Hypoxic molybdenum oxide (MoO3-x ), as a typical nanozyme material, possesses unique physical and chemical properties, showing great potential in fields such as cancer treatment. In this study, a simple and rapid one-pot hydrothermal synthesis method was ingeniously employed, innovatively combining molybdenum, which has high biosafety, with safflower, which exhibits anticancer pharmacological activity, to successfully prepare hypoxic molybdenum oxide (MoO3-x )-doped safflower carbon dots (H-Mo-CDs). H-Mo-CDs exhibit exceptional catalase (CAT)-like, peroxidase (POD)-like, and superoxide dismutase (SOD)-like catalytic activities and superior photothermal conversion efficiency and photostability. In vitro cellular experiments have verified their multiple therapeutic potentials in photothermal therapy (PTT), chemodynamic therapy (CDT), and photodynamic therapy (PDT), providing novel ideas and means for precise cancer treatment. This study not only paves an efficient and feasible path for the development of Mo-based nanomaterials as "smart" nanozymes but also injects new vitality and possibilities into the types and applications of nanozymes in cancer treatment.

Photoinduced Synergism of Ferroptosis/Pyroptosis/Oncosis by an O2-Independent Photocatalyst for Enhanced Tumor Immunotherapy

Due to O2 dependence, hypoxia-induced apoptosis resistance, and immunosuppressive microenvironment, the effect of traditional photodynamic therapy toward hypoxic solid tumors is severely limited. Herein, we report an O2-independent photocatalyst (EBSe) for tumor immunotherapy potentiation via synergism of near-infrared (NIR) light-induced ferroptosis/pyroptosis/oncosis. Simple Se and ethyl modifications on methylene blue (MB) endow EBSe with a remarkable phototoxicity enhancement (>2500 folds) and an excellent phototoxicity index (PI > 32,000) to 4T1 cells under hypoxia. EBSe exhibits self-adaptive photodynamic processes that generate enhanced type I/II ROS under normoxia and elevate carbon radical production under hypoxia. Interestingly, EBSe shows much higher cell uptake and undergoes photoinduced lysosomal-to-nucleus translocation, which activates ferroptosis, pyroptosis, and oncosis. The synergism of three nonapoptotic pathways potentiates antitumor immune responses in 4T1 tumor-bearing mice. This work offers a reliable strategy for developing powerful PSs to overcome the apoptosis resistance and immunosuppressive microenvironment of hypoxic tumors.

Phototherapy in cancer treatment: strategies and challenges

Phototherapy has emerged as a promising modality in cancer treatment, garnering considerable attention for its minimal side effects, exceptional spatial selectivity, and optimal preservation of normal tissue function. This innovative approach primarily encompasses three distinct paradigms: Photodynamic Therapy (PDT), Photothermal Therapy (PTT), and Photoimmunotherapy (PIT). Each of these modalities exerts its antitumor effects through unique mechanisms-specifically, the generation of reactive oxygen species (ROS), heat, and immune responses, respectively. However, significant challenges impede the advancement and clinical application of phototherapy. These include inadequate ROS production rates, subpar photothermal conversion efficiency, difficulties in tumor targeting, and unfavorable physicochemical properties inherent to traditional phototherapeutic agents (PTs). Additionally, the hypoxic microenvironment typical of tumors complicates therapeutic efficacy due to limited agent penetration in deep-seated lesions. To address these limitations, ongoing research is fervently exploring innovative solutions. The unique advantages offered by nano-PTs and nanocarrier systems aim to enhance traditional approaches' effectiveness. Strategies such as generating oxygen in situ within tumors or inhibiting mitochondrial respiration while targeting the HIF-1α pathway may alleviate tumor hypoxia. Moreover, utilizing self-luminescent materials, near-infrared excitation sources, non-photoactivated sensitizers, and wireless light delivery systems can improve light penetration. Furthermore, integrating immunoadjuvants and modulating immunosuppressive cell populations while deploying immune checkpoint inhibitors holds promise for enhancing immunogenic cell death through PIT. This review seeks to elucidate the fundamental principles and biological implications of phototherapy while discussing dominant mechanisms and advanced strategies designed to overcome existing challenges-ultimately illuminating pathways for future research aimed at amplifying this intervention's therapeutic efficacy.

Targeting tumor angiogenesis and metabolism with photodynamic nanomedicine

Photodynamic therapy (PDT) holds considerable promise as a tumor treatment modality, characterized by its targeted action, compatibility with other therapeutic approaches, and non - invasive features. PDT can achieve remarkable spatiotemporal precision in tumor ablation through the generation of reactive oxygen species (ROS). Nevertheless, despite its potential in tumor treatment, PDT encounters multiple challenges in practical applications. PDT is highly oxygen - dependent, and thus the effectiveness of PDT can be markedly influenced by tumor hypoxia. The co-existence of abnormal vasculature and metabolic deregulation gives rise to a hypoxic microenvironment, which not only sustains tumor survival but also undermines the therapeutic efficacy of PDT. Consequently, targeting tumor angiogenesis and metabolism is essential for revitalizing PDT. This review emphasizes the mechanisms and strategies for revitalizing PDT in tumor treatment, predominantly concentrating on interfering with tumor angiogenesis and reprogramming tumor cell metabolism. Lastly, the outlining future perspectives and current limitations of PDT are also summarized. This could provide new insights and methodologies for overcoming the challenges associated with PDT in tumor treatment, ultimately advancing the field of PDT.

Oxidative stress-augmented Cu-doped hollow mesoporous carbon nanozyme for photothermal/photodynamic synergistic therapy

Photodynamic therapy (PDT) has witnessed remarkable progress in recent years owing to its specific properties. Given that the antioxidation system of tumor microenvironment (TME) adversely affects treatment outcomes, powerful TME modulators can significantly resolve the limitation of PDT. Herein, we developed a PEG-modified Cu2+-doped hollow mesoporous carbon nanozyme (CHC-PEG) and loaded insoluble photosensitizer IR780 into its pores and cavities to construct the multifunctional nano-system IR780/CHCP. CHC-PEG nanozyme could perform photothermal therapy (PTT) effect and protect IR780 from aggregation-caused quenching (ACQ) effect, while exerting peroxidase (POD)-mimetic activity and the ability of consuming glutathione (GSH) to achieve oxidative stress-augmented PDT effect. When exposed to near-infrared (NIR) light, IR780 was stimulated to produce singlet oxygen (1O2) and CHC-PEG could increase the temperature of TME to exert stronger POD-mimetic activity for producing more hydroxyl radicals (OH), therefore the IR780/CHCP nano-system exhibited remarkable tumor growth inhibition. Benefited by the enhanced synergistic effect, IR780/CHCP exhibited remarkable in vivo tumor growth inhibition, with the tumor inhibition rate of 93 %, and had no significant effect on major organs. Above all, IR780/CHCP could resist the antioxidant system in TME to enhance the level of oxidative stress, thereby enabling effective anti-tumor therapy. This study introduced a novel strategy to effectively promote the synergistic PTT/PDT effect by the enhanced oxidative stress.

Biomass spinach-drived metal-free carbon dots-based nanozyme for multimodal nitrite sensing and functionalized by glucose oxidase as ROS amplifiers to enhance tumor therapy

The metal-free carbon dots (CDs) nanozyme, which is endowed generation of multiple reactive oxygen species (ROS), followed by highly selective chemical sensing, remains a critical challenge. The exceptional biocatalytic properties of glucose oxidase (GOx) have spurred the development of GOx-functionalized nanocatalysts for cancer therapy. Here, the innovative free metal-doped CDs and CDs@GOx nanozymes with peroxidase (POD)-like activity were developed, which specifically catalyzed H₂O₂ to engender multiple ROS including •O2-, 1O2 and •OH, to oxidize colorless 3,3',5,5'-tetramethylbenzidine (TMB) to blue ox-TMB, indicating both nanozymes can be as ROS amplifiers to enhance tumor therapy. The introduction of NO₂- triggered a distinct color change from blue to green ascribed to the diazotization of ox-TMB along with quenching the fluorescence of CDs, which endowed high selectivity and sensitivity for NO2- detection. Furthermore, CDs catalyzed endogenous H₂O₂ within tumor cells, to effectively destroy cancer cells rather than normal cells. As expected, CDs@GOx preferentially catalyze glucose in cancer cells to further supply H2O2, allowing more ROS accumulation, thereby realizing the integration of starvation therapy and ROS therapy of cancer. Notably, in vivo anti-tumor efficacy demonstrated that CDs and CDs@GOx markedly inhibited tumor growth without external stimulation with neglected side effects. Compared to the saline group, the tumor size was reduced by 3 or 4 times for CDs and CDs@GOx, respectively. This metal-free CDs tailors a convenient and impactful nanoplatform for chemical sensing and as ROS amplifiers to enhance tumor therapy by non-invasive treatment.

Regio-isomerization Optimization Strategy for Photosensitizers: Achieving Ultrahigh Type I Reactive Oxygen Species Generation to Enhance Cancer Photoimmunotherapy

Phototherapy, renowned for its noninvasiveness, is widely employed in tumor treatment. However, the tumor microenvironment is usually hypoxic, with insufficient reactive oxygen species (ROS) production, severely limiting its application. Herein, we introduce a regio-isomerization optimization strategy and have synthesized four regio-isomeric photosensitizers featuring a donor-acceptor (D-A) configuration by tactically varying the linkage sites between D and A. Among them, TAF-3 with excellent photostability has an ultrahigh type I ROS production efficiency (4.79 times that of methylene blue) and a photothermal conversion efficiency of 41.7%. TAF-3 improves the conjugation degree; produces an appropriate intramolecular charge transfer effect, which enhances its optical properties and phototherapeutic efficiency; and promotes a stronger immune cell death effect, reducing postoperative melanoma recurrence by 60%. Overall, the optical attributes of D-A type photosensitizers can be tailored through the precision modulation of regio-isomerization, offering a promising avenue for the advancement of clinical photosensitizers suitable for phototherapy.

Evolution of nMOFs in photodynamic therapy: from porphyrins to chlorins and bacteriochlorins for better efficacy

Photodynamic therapy (PDT) has gained significant attention due to its non-invasive nature, low cost, and ease of operation. Nanoscale metal-organic frameworks (nMOFs) incorporating porphyrins, chlorins, and bacteriochlorins have emerged as one of the most prominent photoactive materials for tumor PDT. These nMOFs could enhance the water solubility, stability and loading efficiency of photosensitizers (PSs). Their highly ordered porous structure facilitates O2 diffusion and enhances the generation of 1O2 from hydrophobic porphyrins, chlorins, and bacteriochlorins, thereby improving their efficacy of phototherapy. This review provides insights into the PDT effects of nMOFs derived from porphyrins, chlorins, and bacteriochlorins. It overviews the design strategies, types of reactive oxygen species (ROS), ROS generation efficiency, and the unique biological processes involved in inhibiting tumor cell proliferation, focusing on the mechanism by which molecular structure leads to enhanced photochemical properties. Finally, the review highlights the new possibilities offered by porphyrins, chlorins, and bacteriochlorins-based nMOFs for tumor PDT, emphasizing how optimized design can further improve the bioapplication of porphyrin derivatives represented PSs. With ongoing research and technological advancements, we anticipate that this review will garner increased attention from scientific researchers toward porphyrin-based nMOFs, thereby elevating their potential as a prominent approach in the treatment of malignant tumors.

An endoplasmic reticulum and lipid droplets dual-localized strategy to develop small molecular photosensitizers that induce ferroptosis during photodynamic therapy

Organelle-localized photosensitizers have been well-developed to enhance the photodynamic therapy (PDT) efficacy through triggering given cell death. The endoplasmic reticulum (ER) and lipid droplets (LDs) are two key organelles mutually regulating ferroptosis. Thus, in this study, small molecular photosensitizer CAR PSs were developed through fragment integration strategy and the heavy-atom modification. It was showed that the integration strategy did not affect the organelle localization and CAR PSs successfully achieved ER/LDs dual location. Besides, the heavy-atom modification help CAR PSs display good ROS generation efficiency. Importantly, ER/LDs dual-localized CAR PSs exhibited superior photo-toxicity and lower dark-toxicity against multiple breast cancer cell lines than the only ER-targeting Ce6, which further explained the superposition effect of dual organelle targeting. Preliminary studies revealed that CAR PSs induced enhanced ferroptosis via simultaneously triggering the ER stress and lipid peroxidation during PDT. Moreover, CAR-2 demonstrated significant in vivo PDT activity to suppress the tumor growth in 4T1 tumor bearing mice. These findings not only provide a promising photosensitizer CAR-2 exerting excellent in vitro and in vivo PDT effect through stimulating ferroptosis, but also propose a design strategy for the development of ER/LDs dual localized PSs.

Flexible Formation of Nanoparticles: Selectively Self-Assembling with Glycoclusters to Form Nano-Photosensitizers for Multipurpose Bioimaging and Photodynamic Therapy

The smart construction of nano-photosensitizers (PSs) is significant for multipurpose applications, such as bioimaging, efficient photodynamic anti-tumor or anti-bacterial studies. This work reports a flexible self-assembling strategy for the construction of nano-PSs, in which PSs spontaneously form amorphous aggregates for killing bacteria, or self-assemble with tetraphenylethene (TPE) based glycoclusters (TPE-Glc4) to construct glyco-dots for cell imaging and photodynamic anti-tumor studies. Tricyanofuran (TCF) and TPE units were bridged with furan or thiophene moiety to construct two PSs (1 and 2) with NIR fluorescence in monomers, and a performance of the aggregation-induced generation of reactive oxygen species (AIG-ROS) in an aggregated state. Compared to the large amorphous aggregates (2-a), TPE-based glycoclusters encapsulated with PS form glyco-dots (2-Glc) that exhibit a smaller and more homogeneous hydrated size of approximately 40 nm, as well as enhanced water-solubility and biocompatibility. TPE-glycoclusters facilitate the cellular uptake of 2 into HepG2 cells, therefore enhancing the NIR fluorescence imaging signal and photodynamic therapy. Meanwhile, 2-a exhibits satisfied phototoxicity against Escherichia coli. This work highlights the flexible self-assembly of nano-PSs for multifunctional bioapplications.

A nano drug delivery system loading drugs and chlorin e6 separately to achieve photodynamic-chemo combination therapy

AIM

To develop a new drug delivery system (DDS) that can load chemotherapy agents and photosensitizer chlorin e6 (Ce6) onto the pores and surfaces of mesoporous silica nanoparticle (MSN) separately.

METHODS

Doxorubicin (DOX) was loaded into the pores of MSNs. Then, polyethyleneimine (PEI) was used to coat the surface of MSN to protect DOX, and then manganese dioxide (MnO2) nanoparticles were loaded through adding potassium permanganate (KMnO4) to bind with Ce6. Finally, polydopamine (PDA) was coated and coupled with hyaluronic acid (HA).

RESULTS

The synthesized versatile nanoparticle was pH-sensitive and exhibited positive photodynamic therapy (PDT) performance. Besides, it could be observed that the nanoparticles were efficiently taken up by tumor cells through confocal laser scanning microscopy (CLSM) and flow cytometry. Additionally, in vitro experiments suggested that the nanoparticles had pleasing toxicity to various tumor cells and equally positive therapeutic effect when curcumin replaced DOX.

CONCLUSION

Our work suggests that the nanoparticles designed by our strategy have satisfactory combination therapy performance and can enable more chemotherapy drugs to be used in photodynamic-chemo combination therapy.

Applications and enhancement strategies of ROS-based non-invasive therapies in cancer treatment

Reactive oxygen species (ROS) play a crucial role in the pathogenesis of cancer. Non-invasive therapies that promote intracellular ROS generation, including photodynamic therapy (PDT), sonodynamic therapy (SDT), and chemodynamic therapy (CDT), have emerged as novel approaches for cancer treatment. These therapies directly kill tumor cells by generating ROS, and although they show great promise in tumor treatment, many challenges remain to be addressed in practical applications. Firstly, the inherent complexity of the tumor microenvironment (TME), such as hypoxia and elevated glutathione (GSH) levels, hinders ROS generation, thereby significantly diminishing the efficacy of ROS-based therapies. In addition, these therapies are influenced by their intrinsic mechanisms. To overcome these limitations, various nanoparticle (NP) systems have been developed to improve the therapeutic efficacy of non-invasive therapies against tumors. This review first summarizes the mechanisms of ROS generation for each non-invasive therapy and their current limitations, with a particular focus on the enhancement strategies for each therapy based on NP systems. Additionally, various strategies to modulate the TME are highlighted. These strategies aim to amplify ROS generation in non-invasive therapies and enhance their anti-tumor efficiency. Finally, the current challenges and possible solutions for the clinical translation of ROS-based non-invasive therapies are also discussed.

Induction of ferroptosis of iridium(III) complexes localizing at the mitochondria and lysosome by photodynamic therapy

In this study, [Ir(ppy)2(DMHBT)](PF6) (ppy = deprotonated 1-phenylpyridine, DMHBT = 10,12-dimethylpteridino[6,7-f][1,10]phenanthroline-11,13-(10,12H)-dione, 8a), [Ir(bzq)2(DMHBT)](PF6) (bzq = deprotonated benzo[h]quinoline, 8b) and [Ir(piq)2(DMHBT)](PF6) (piq = deprotonated 1-phenylisoquinoline, 8c) were synthesized and characterized by HRMS, 13C NMR and 1H NMR. In vitro cytotoxicity experiments showed that 8a, 8b, 8c show moderate cytotoxicity against B16 cells, while the cytotoxicity of the complexes 8a, 8b and 8c toward B16 cells was greatly improved upon light irradiation, which can be used as photosensitizers to exert anticancer efficacy in photodynamic therapy (PDT). After being taken up by cells, 8a, 8b, 8c were localized in the mitochondria, resulting in a large amount of Ca2+ in-flux, a burst release of ROS, a sustained opening of mitochondrial permeability transition pore, and a decrease of the mitochondrial membrane potential, which led to mitochondrial dysfunction and further activation of caspase 3 and Bcl-2 family proteins to induce apoptosis. Overloaded ROS reacted with polyunsaturated fatty acids on the cell membrane, and initiated lipid peroxidation, inhibited the xc--system-glutathione (GSH)-glutathione peroxidase 4 (GPX4) antioxidant defense system, and upregulated the expression of the damage-associated molecules, HMGB1, CRT, and HSP70. The presence of Fer-1 was effective on increasing the cell survival, which demonstrates that the complexes possess the potential to induce ferroptosis and immunogenic cell death. In addition, 8a, 8b and 8c induced autophagy by inhibiting the AKT/PI3K/mTOR signaling pathway, downregulating p62 and promoting Beclin-1 expression upon light irradiation.

An Albumin-Photosensitizer Supramolecular Assembly with Type I ROS-Induced Multifaceted Tumor Cell Deaths for Photodynamic Immunotherapy

Photodynamic therapy holds great potentials in cancer treatment, yet its effectiveness in hypoxic solid tumor is limited by the oxygen-dependence and insufficient oxidative potential of conventional type II reactive oxygen species (ROS). Herein, the study reports a supramolecular photosensitizer, BSA@TPE-BT-SCT NPs, through encapsulating aggregation-enhanced emission photosensitizer by bovine serum albumin (BSA) to significantly enhance ROS, particularly less oxygen-dependent type I ROS for photodynamic immunotherapy. The abundant type I ROS generated by BSA@TPE-BT-SCT NPs induce multiple forms of programmed cell death, including apoptosis, pyroptosis, and ferroptosis. These multifaceted cell deaths synergistically facilitate the release of damage-associated molecular patterns and antitumor cytokines, thereby provoking robust antitumor immunity. Both in vitro and in vivo experiments confirmed that BSA@TPE-BT-SCT NPs elicited the immunogenic cell death, enhance dendritic cell maturation, activate T cell, and reduce myeloid-derived suppressor cells, leading to the inhibition of both primary and distant tumors. Additionally, BSA@TPE-BT-SCP NPs also exhibited excellent antitumor performance in a humanized mice model, evidenced by a reduction in senescent T cells among these activated T cells. The findings advance the development of robust type I photosensitizers and unveil the important role of type I ROS in enhancing multifaceted tumor cell deaths and antitumor immunogenicity.

Ru(II) Complexes with 3,4-Dimethylphenylhydrazine: Exploring In Vitro Anticancer Activity and Protein Affinities

Two new Ru(II) complexes, mononuclear [RuCl2(η6-p-cymene)(3,4-dmph-κN)] (1) and the binuclear complex [{RuCl(η6-p-cymene)}2(μ-Cl)(μ-3,4-dmph-κ2N,N')]Cl (2; 3,4-dmph = 3,4-dimethylphenylhydrazine), are synthesized and experimentally and theoretically structurally characterized utilizing 1H and 13C NMR and FTIR spectroscopy, as well as DFT calculations. Degradation product of 2, thus ([{RuCl(η6-p-cymene)}2(μ-Cl)(μ-3,4-dmph-κ2N,N')][RuCl3(η6-p-cymene)] (2b) was characterized with SC-XRD. In the crystals of 2b, the cationic and anionic parts interact through N-H...Cl hydrogen bridges. The spectrofluorimetric measurements proved the spontaneity of the binding processes of both complexes and HSA. Spin probing EPR measurements implied that 1 and 2 decreased the amount of bound 16-doxylstearate and implicated their potential to bind to HSA more strongly than the spin probe. The cytotoxicity assessment of both complexes against the MDA-MB-231 and MIA PaCa-2 cancer cell lines demonstrated a clear dose-dependent decrease in cell viability and no effect on healthy HS-5 cells. Determination of the malondialdehyde and protein carbonyl concentrations indicated that new complexes could offer protective antioxidant benefits in specific cancer contexts. Gel electrophoresis measurements showed the reduction in MMP9 activity and indicated the potential of 1 in limiting the cancer cells' invasion. The annexin V/PI apoptotic assay results showed that 1 and 2 exhibit different selectivity towards MIA PaCa-2 and MDA-MB-231 cancer cells. A comparative molecular docking analysis of protein binding, specifically targeting acetylcholinesterase (ACHE), matrix metalloproteinase-9 (MMP-9), and human serum albumin (HSA), demonstrated distinct binding interactions for each complex.

Advances in cuproptosis harnessing copper-based nanomaterials for cancer therapy

Cuproptosis, a newly identified programmed cell death form, is characterized by excessive copper accumulation in cells, resulting in mitochondria damage and toxic protein stress, ultimately causing cell death. Given the considerable therapeutic promise of copper toxicity in cancer treatment, copper-based nanomaterials that induce copper death have attracted interest as a promising approach for tumor therapy. This review comprehensively introduces the mechanisms of cuproptosis and the associated regulatory genes, including both positive and negative regulatory regulators, and systematically summarizes the application of various nanoparticles in inducing cuproptosis, ranging from inorganic copper compounds to delivery systems. These nanoparticles offer significant advantages, such as improving copper absorption, extending the duration of effectiveness, enhancing the precision of copper release, increasing biocompatibility, and serving as enhancers in combination therapy. In conclusion, the authors present a detailed overview and insights into the current research directions of nanoplatforms that facilitate copper-induced cancer treatment, establishing a foundation for the future development of effective nanomedicines that induce cuproptosis and offering new possibilities and treatment strategies for tumor therapy.

Oxygen self-supplying porphyrinic MOFs to alleviate tumor hypoxia for starvation-amplified photodynamic therapy

An oxygen self-supplying nanoplatform utilizing perfluorocarbon-functionalized porphyrinic MOFs was developed to alleviate tumor hypoxia. This strategy combines external oxygen-delivery with in situ oxygen generation via cascade reactions, resulting in enhanced synergistic effects for both cancer starvation therapy and robust photodynamic therapy.

Mitochondria-localized dinuclear iridium(III) complexes for two-photon photodynamic therapy

Photodynamic therapy (PDT), as a non-invasive cancer treatment, offers significant advantages including high temporal-spatial selectivity, minimal surgical intervention, and low toxicity, thereby garnering considerable research interest from across the world. In this study, we have developed a series of dinuclear cyclometalated Ir(III) complexes as potential two-photon photodynamic anticancer agents. These Ir(III) complexes demonstrate significant two-photon absorption (2PA) cross-sections (σ2 = 66-166 GM) and specifically target mitochondria. Amongst them, N-Ir4 manifests an IC50 value of 2.0 μM and a phototoxicity index (PI) of 24. Under two-photon excitation, N-Ir4 efficiently generates reactive oxygen species (ROS), leading to mitochondrial damage and cell death. Our study reveals drastically enhanced optical properties forged by forming a dinuclear complex bridged by two conjugated rigid planar moieties and sheds light on a potential paradigm to boost 2PA cross-sections.

Design strategies and biomedical applications of organic NIR-IIb fluorophores

The introduction of fluorescence imaging (FLI) in near-infrared II sub-channels (NIR-IIb, 1500-1700 nm) has revolutionized the ability to explore complex patho-physiological settings in vivo. Despite the transformative potentials, the development of organic NIR IIb dyes encounters considerable difficulties, and only a limited number of such fluorophores have been developed so far. This review systematically introduces design strategies of organic NIR-IIb fluorophores classified by molecular scaffolds, mainly including cyanine dyes and D-A-D small molecule dyes. The design strategies of cyanine dyes involve repurposing of the existing NIR dyes, conjugate reinforcement and regulation of the aggregation state. For D-A-D small molecule dyes, strategies mainly incorporate the extension of the conjugate skeleton, introduction of shielding units, and acceptor/donor engineering. We further describe recent biomedical applications including biomedical imaging and imaging-guided therapy, and conclude by clarifying the current challenges and prospects of NIR-IIb FLI.

pH-Activatable NIR Hemicyanine for Mitochondria-Targeted Cancer Phototheranostics

Photodynamic therapy (PDT) has garnered significant attention for cancer treatment due to its noninvasive nature, reduced drug resistance, and spatiotemporal controllability. However, traditional photosensitizers (PSs) face limitations such as severe systemic phototoxicity and shallow tissue penetration, which hinder the widespread clinical application of PDT. Capitalizing on the strong near-infrared (NIR) absorption and ease of structural modification of hemicyanine, we have designed a pH-activatable NIR hemicyanine PS (LET-15). It is specifically activated in the acid tumor microenvironment, subsequently targeting mitochondria and generating cytotoxic singlet oxygen under 660 nm laser irradiation, which selectively destroys tumor tissues while minimizing damage to healthy tissues. Additionally, it offers activatable fluorescence (FL) imaging with a high signal-to-noise ratio, enabling FL imaging-assisted tumor photoeradication. This study provides valuable guidance for designing tumor-specifically activated NIR PSs for precision PDT.

Photoredox-Mediated Immunotherapy Utilizing Rhenium(I) Photocatalysts with Electron Donor-Acceptor-Donor Configuration

The hypoxic environment of solid tumors significantly diminishes the therapeutic efficacy of oxygen-dependent photodynamic therapy. Developing efficient photosensitizers that operate via photoredox catalysis presents a promising strategy to overcome this challenge. Herein, we report the rational design of two rhenium(I) tricarbonyl complexes (Re-TPO and Re-TP) with electron donor-acceptor-donor configuration. Notably, Re-TP exhibits aggregation-induced emission properties and enhanced spin-orbit coupling compared to Re-TPO, thus exhibiting promoted photosensitizing capability. In addition to generating type I and II reactive oxygen species, the excited Re-TP facilitates the photocatalytic oxidation of NADH to NAD+ and the photoreduction of pyruvic acid to lactic acid. This metabolic intervention triggers PD-L1-linked immune responses and disrupts tumor redox balance, leading to ferroptosis and immunogenic cell death. The combined ferroptosis and immunotherapy effects significantly suppress both primary and distant B16 tumors. This investigation provides a compelling model for designing efficient metal-based PSs for photoredox-mediated photoimmunotherapy against hypoxic tumors.

A Hypoxia-Activated BODIPY-Azo Anticancer Prodrug for Bimodal Chemo-Photodynamic Therapy

For cancer treatment, collaborative strategies have been the mainstream for overcoming the restrictions resulting from monotherapy. Combining chemotherapy with photodynamic therapy (PDT) has been shown to increase the antitumor effect and reduce side impacts. This study reports a hypoxia-activated prodrug BOD-Azo-single with a PDT agent and aniline mustard connected by the azo bond. With light illumination, BOD-Azo-single exhibited some PDT. Under hypoxic conditions, the azo bond cleaved and released BOD-3-single of higher phototoxicity and aniline mustard of chemotoxicity. In vivo therapeutic experiments showed that BOD-Azo-single with light significantly reduced A375 tumor proliferation with 92% TGI value. Overall, in this study, PDT was employed to address the adverse systemic toxicity of chemotherapy and the released chemotoxicity made up for the inefficiency of PDT in the hypoxic tumor microenvironment, introducing a new strategy for developing combined therapeutic agents to be advantageous to each other. Under a hypoxic tumor environment, BOD-3-single and aniline mustard exerted a strong synergistic effect (CI = 0.25), indicating that BOD-Azo-single is a real bimodal chemo-photodynamic therapeutic agent.

Calcination-Induced Tight Nano-Heterointerface for Highly Effective Eradication of Rib Fracture-Related Infection by Near-Infrared Irradiation

Rib fracture-related infection is a challenging complication of thoracic trauma due to the difficulty of treating it with antibiotics alone and the need for a second operation to remove the infected fixator and sterilize the surrounding infected tissue. In this study, inspired by the photocatalytic performance of and ion release from silver-based materials, including Ag3PO4 and Ag2S, a hybrid Ag3PO4-Ag2S heterojunction was prepared based on in situ anion exchange and a one-step calcination process to design a nonantibiotic coating aimed at preventing and treating rib fracture-related infection with short-term 808 nm near-infrared irradiation. Calcination at 250 °C enhanced the inductive effect of the phosphate radical and led to the formation of a tight nanoheterogeneous interface between Ag3PO4 and Ag2S, thereby promoting interfacial electron transfer and reducing the recombination of photogenerated carriers. The result was improved photodynamic performance of the Ag3PO4-Ag2S coating. Moreover, metal-Ag3PO4-Ag2S had a significant photothermal effect and released only a small amount of Ag+. The synergy of Ag3PO4-Ag2S endowed the coating with high antibacterial efficacy, eliminating 99.90 ± 0.05 and 99.95 ± 0.03% of Staphylococcus aureus and Escherichia coli, respectively, after 15 min of NIR irradiation in vitro, and 99.66 ± 0.13% of Staphylococcus aureus in vivo. This biocompatible Ag3PO4-Ag2S coating exhibited superb efficacy in eliminating rib fracture-related infection and reducing the associated inflammation.

Multifunctional Cu3BiS3-BP@PEI Radiosensitizer with Enhanced Reactive Oxygen Species Activity for Multimodal Synergistic Therapy

Development of radiosensitizers with high-energy deposition efficiency, electron transfer, and oxidative stress amplification will help to improve the efficiency of radiotherapy. To overcome the drawbacks of radiotherapy alone, it is also crucial to design a multifunctional radiosensitizer that simultaneously realizes multimodal treatment and tumor microenvironment modulation. Herein, a multifunctional radiosensitizer based on the Cu3BiS3-BP@PEI nanoheterostructure (NHS) for multimodal cancer treatment is designed. Cu3BiS3-BP@PEI NHS is able to deposit a high radiation dose into cancer cells, enhancing the radiotherapy effect. Due to the heterostructure and the synergistic effect of Cu3BiS3 and black phosphorus (BP), significantly boosted 1O2 and •OH generation is obtained under X-ray irradiation, which is promising for extremely efficient radiodynamic therapy. More importantly, the acidic tumor microenvironment (TME) can induce the cycle conversion of Cu2+ to Cu+, oxidizing glutathione (GSH) and catalyzing intracellular overproduction of H2O2 into highly toxic •OH, which thus further enhances reactive oxygen species (ROS) production and reduces GSH-associated radioresistance. Furthermore, Cu3BiS3-BP@PEI NHS has an excellent photothermal effect and can effectively transform light into heat. The outcomes of the in vitro and in vivo research confirm that the as-prepared Cu3BiS3-BP@PEI NHS has a high synergistic therapeutic efficacy at a low radiation dose. This work provides a viable approach to constructing a multifunctional radiosensitizer for deep tumor treatment with TME-triggered multiple synergistic therapies.

A novel cyanine photosensitizer for sequential dual-site GSH depletion and ROS-potentiated cancer photodynamic therapy

The efficacy of photodynamic therapy (PDT) is often limited by the reductive microenvironment in tumor cells due to the high level of glutathione (GSH) and glutathione peroxidase 4 (GPX4), which maintain redox homeostasis. Therefore, designing a GSH-responsive photosensitizer that depletes intracellular GSH is a promising strategy to enhance PDT selectivity and efficacy. Herein, we present a GSH-selective sequentially responsive theranostic photosensitizer, Cy-Res. This cyanine agent targeting mitochondria effectively depletes two GSH molecules, leading to the generation of abundant ROS and exacerbating oxidative stress. Additionally, it achieves an 80-fold fluorescence enhancement upon response to GSH, enabling selective imaging of tumor cells. By mitigating GSH's impact on PDT, Cy-ResNPs achieves synergistic and efficient PDT treatment of invasive melanoma under low-power irradiation (808 nm, 80 mW/cm2). The inhibitory processes downregulate GPX4, increase apoptotic proteins like Bax, and promote mixed cell death involving both ferroptosis and apoptosis. Overall, this study offers new insights and strategies for the development of GSH-responsive theranostic agents, highlighting their potential for application in tumor diagnosis and therapy.

Sialic Acid-Modified NIR-II Fluorophore with Enhanced Brightness and Photoconversion Capability for Targeted Lymphoma Phototheranostics

Lymphoma is a malignant cancer characterized by a rapidly increasing incidence, complex etiology, and lack of obvious early symptoms. Efficient theranostics of lymphoma is of great significance in improving patient outcomes, empowering informed decision-making, and driving medical innovation. Herein, we developed a multifunctional nanoplatform for precise optical imaging and therapy of lymphoma based on a new photosensitizer (1-oxo-1H-benzoo[de]anthracene-2,3-dicarbonitrile-triphenylamine (OBADC-TPA)). OBADC-TPA is a donor-acceptor (D-A) molecule characterized by a novel small coplanar and strong electron-withdrawing acceptor skeleton, while the OBADC moiety facilitates strong intramolecular charge transfer. OBADC-TPA-based nanoparticles (NPs) were prepared through encapsulation with an amphiphilic polymer and subsequent modification with sialic acid (SA). Both in vitro and in vivo studies demonstrated that NPs-SA possessed good biocompatibility, effective tumor accumulation, high photoacoustic (PA) contrast, bright second near-infrared (NIR-II) fluorescence emission, and efficient photothermal/photodynamic conversion capabilities, which can serve as a multifunctional nanocomposite for targeted PA/NIR-II fluorescence imaging-guided synergistic type I/II photodynamic and photothermal therapy (PDT/PTT) of lymphoma. This work not only provides a new NIR-II fluorophore with a novel acceptor moiety but also offers a new, accurate, and effective approach for the targeted diagnosis and treatment of lymphoma, holding promising prospects for clinical application.

The Current Advances in Design Strategy (Indirect Strategy and Direct Strategy) for Type-I Photosensitizers

Type-I photosensitizers (PSs) are among the most potential candidates for photodynamic therapy (PDT), as their low dependence on oxygen endow them with many advantages for treating hypoxic tumor. However, most of the reported type-I PSs have a contingency of molecular design, because electron transfer (ET) reaction is more difficult to achieve than energy transfer (EET) process. Therefore, it is urgent to understand molecular design mechanisms for type-I PSs. In this review, the two ways to achieve the type-I PSs, i.e., inhibiting EET process (type-II) or enhancing ET process (type-I), are detailly explained. In response, the current design strategies of type-I PSs are summarized from two perspectives: indirect strategy (inhibiting EET process: reducing the energy of the lowest triplet excited state (T1) to lower than the energy required for the excitation energy transfer to produce singlet oxygen) and direct strategy (enhancing ET process: promoting the ET efficiency of PSs to generate superoxide radicals). The construction of direct strategy can be realized by forming an electron-rich microenvironment, providing an electron-deficient intermediate transmitter, and introducing an enhanced electron transfer capacity primitive.

One-Pot Synthesis of Oxygen Vacancy-Rich Amorphous/Crystalline Heterophase CaWO4 Nanoparticles for Enhanced Radiodynamic-Immunotherapy

Radiodynamic therapy that employs X-rays to trigger localized reactive oxygen species (ROS) generation can tackle the tissue penetration issue of phototherapy. Although calcium tungstate (CaWO4) shows great potential as a radiodynamic agent benefiting from its strong X-ray absorption and the ability to generate electron-hole (e--h+) pairs, slow charge carrier transfer and fast e--h+ recombination greatly limit its ROS-generating performance. Herein, via a one-pot wet-chemical method, oxygen vacancy-rich amorphous/crystalline heterophase CaWO4 nanoparticles (Ov-a/c-CaWO4 NPs) with enhanced radiodynamic effect are synthesized for radiodynamic-immunotherapy of cancer. The phase composition and oxygen vacancy content of CaWO4 can be easily tuned by adjusting the solvothermal temperature. More intriguingly, the amorphous/crystalline interfaces and abundant oxygen vacancies accelerate charge carrier transfer and suppress e--h+ recombination, respectively, enabling synergistically improved ROS production from X-ray-irradiated Ov-a/c-CaWO4 NPs. In addition to directly inducing oxidative damage of cancer cells, radiodynamic generation of ROS also boosts immunogenic cell death to provoke a systemic antitumor immune response, thereby allowing the inhibition of both primary and distant tumors as well as cancer metastasis. This study establishes a synergistic enhancement strategy involving the integration of phase and defect engineering to improve the ROS generation capacity of radiodynamic-immunotherapeutic anticancer nanoagents.

Modulation of Donor in Purely Organic Triplet Harvesting AIE-TADF Photosensitizer for Image-guided Photodynamic Therapy

Image-guided photodynamic therapy is acknowledged as one of the most demonstrative therapeutic modalities for cancer treatment because of its high precision, non-invasiveness, and improved imaging ability. A series of purely organic photosensitizers denoted as BTMCz, BTMPTZ, and BTMPXZ, have been designed and synthesized and are found to exhibit both thermally activated delayed fluorescence and aggregation-induced emission simultaneously. Experimental and theoretical studies are combined to reveal that modulation of the donor of the photosensitizer enables distinct thermally activated delayed fluorescence via a second-order spin-orbit perturbation mechanism involving lowest singlet charge-transfer and higher-lying triplet locally excited states, respectively. Further, different donor strengths and unique aggregations (H-, J- and X-type packings) greatly influence their color-tunable up-converted luminescence and endow them with superb dispersibility in water. The confocal microscopy-based cellular uptake study confirms the successful internalization of the nano-probes, while BTMCz enables the generation of reactive oxygen species (singlet oxygen) under white-light irradiation, enabling the efficient killing of cancer cells.

Developing Chlorin/Arylaminoquinazoline Conjugates with Nanomolar Activity for Targeted Photodynamic Therapy: Design, Synthesis, SAR, and Biological Evaluation

In this report, we developed novel chlorin/arylaminoquinazoline conjugates for targeted photodynamic therapy of cancer. The synthesized photosensitizers consisted of chlorin-e6 metallocomplexes (Zn, In, or Pd) conjugated with arylaminoquinazoline ligands with high affinity for epidermal growth factor receptors (EGFR). Additionally, the selectivity and antitumor properties of the conjugates were investigated in the EGFR-expressing A431 human tumor cell line in vitro. Among the tested molecules, the In-containing conjugate effectively inhibited tumor cell proliferation at nanomolar concentrations, a rare property for conventional photosensitizers. In in vivo experiments, the conjugates rapidly accumulated at the tumor site in nude mice bearing A431 xenograft tumors. Subsequent distribution analysis among different tissues was carried out using fluorescence imaging and elemental analysis. Finally, we demonstrated that the most promising In-containing conjugate was capable of inhibiting xenograft tumor growth in mice through combinational therapy. This therapeutic approach, combined with the conjugate's confirmed safety profile, highlights its potential for effective and safe cancer treatment.

Multi-scale numerical simulations of photothermal therapy for tumors based on PDA-coated gold nanoparticles

This paper presents a multiscale computational model, 'micro-to-meso-to-macro', to simulate polydopamine coated gold nanoparticles (AuNP@PDA) for assisted tumor photothermal therapy (PTT). The optical properties, mainly refractive index, of the PDA unit molecules are calculated using the density functional theory (DFT) method in this multiscale model. Subsequently, the thermodynamic properties, including thermal conductivity and heat capacity, of the PDA cells and AuNP@PDA particles are calculated using molecular dynamics (MD) simulation. The absorption and scattering coefficients of the AuNP@PDA particle at the mesoscale were calculated using the finite element method (FEM) with the given input parameters. Subsequently, the photothermal conversion ratio was calculated. Finally, the photothermal conversion ratio was used in the macroscale PTT model to calculate the tumor temperature and thermal damage ratio. The calculated absorption peak of AuNP@PDA is red-shifted by 32 nm compared to that of AuNPs, while the experimental value was 38 nm. The photothermal conversion ratio of AuNP@PDA is 35.33%, which is higher than that of AuNPs (21.31%). The experimental values of AuNP@PDA and AuNPs were 33% and 23%, respectively. Moreover, the temperature change of the AuNP@PDA solution after laser irradiation closely matched the experimental findings. The results indicate the validity of the multiscale method used in this study. This multiscale computational strategy provides new insight into the study of the properties of complex systems in the absence of experimental material property data.

NIR-Activable Charge Transfer Agents for Synergistic Photoimmunotherapy

The combination of photothermal therapy (PTT) and photodynamic therapy (PDT) has become an attractive tumor treatment modality, yet the facile design of photoimmunotheranostic agents with efficient near infrared (NIR) light-absorbing and immune-activating capabilities remains a tremendous challenge. Herein, we developed a NIR-activable organic charge transfer complex (CTC), with perylene (PER) as the electron donor and 4,5,9,10-tetrabromoisochromeno [6,5,4-def]isochromene-1,3,6,8-tetraone (Br4NDI) as the electron acceptor. Through further supramolecular assembly, the PER-Br4NDI nanoparticle (PBND NP) for spatiotemporally controlled photoimmunotherapy was constructed. The PBND NP exhibits superb NIR absorption, robust intermolecular charge transfer, and enhanced intersystem crossing. Upon NIR photoirradiation, the PBND NP effectively exerts photothermal and photodynamic effects with a remarkable photothermal conversion efficiency of 63.5 % and a high reactive oxygen species generation capability, which not only directly ablates primary tumors, but also dramatically suppresses distant tumor growth via promoted immunogenic cell death. Moreover, programmed cell death protein 1 antibody acts synergistically to block immune evasion and ultimately enhances cancer treatment efficacy. This work therefore sheds light on the design of organic CTCs for synergistic photoimmunotherapy.

Advances in nanoparticle-based radiotherapy for cancer treatment

Radiotherapy has long been recognized as an effective conventional approach in both clinical and scientific research, primarily through mechanisms involving DNA destruction or the generation of reactive oxygen species to target tumors. However, significant challenges persist, including the unavoidable damage to normal tissues and the development of radiation resistance. As a result, nanotechnology-based radiotherapy has garnered considerable attention for its potential to enhance precision in irradiation, improve radiosensitization, and achieve therapeutic advancements. Importantly, radiotherapy alone frequently falls short of fully eradicating tumors. Consequently, to augment the efficacy of radiotherapy, it is often integrated with other therapeutic strategies. This review elucidates the mechanisms of radiotherapy sensitization based on diverse nanoparticles. Typically, radiotherapy is sensitized through augmenting reactive oxygen species production, targeted radiotherapy, hypoxia relief, enhancement of antitumor immune microenvironment, and G2/M cell cycle arrest. Moreover, the incorporation of nanoparticle-based anti-tumor strategies with radiotherapy markedly enhances the current state of radiotherapy. Additionally, a compilation of clinical trials utilizing nano-radioenhancers is presented. Finally, future prospects for clinical translation in this field are thoroughly examined.

Acid-responsive singlet oxygen nanodepots

The singlet oxygen carrier addresses the challenges of traditional photodynamic therapy (PDT), which relies on the presence of oxygen within solid tumors and struggles with light penetration issues. However, the inability to control the release of singlet oxygen has hindered precise treatment applications. Here, we introduce an acid-responsive singlet oxygen nanodepot (aSOND) designed to overcome this limitation. The aSOND is synthesized using a responsive diblock copolymer system that includes a hydrophilic PEG block and a pH-responsive block with singlet oxygen loading sites. In neutral or alkaline environments, the aSOND releases singlet oxygen slowly, ensuring stability in blood circulation. In contrast, in acidic environments such as the tumor microenvironment or intracellular lysosomes, protonation of the tertiary amine group within the pH responsive block increases the hydration of the polymer, triggering a rapid release of singlet oxygen. This feature enables controlled, tumor-specific release of reactive oxygen species (ROS). The aSOND system effectively implements an "OFF-ON" singlet oxygen therapy, demonstrating high spatiotemporal selectivity and independence from both oxygen supply and external light, offering a promising approach for targeted cancer therapy.

Finely Tailored Conjugated Small Molecular Nanoparticles for Near-Infrared Biomedical Applications

Near-infrared (NIR) phototheranostics (PTs) show higher tissue penetration depth, signal-to-noise ratio, and better biosafety than PTs in the ultraviolet and visible regions. However, their further advancement is severely hindered by poor performances and short-wavelength absorptions/emissions of PT agents. Among reported PT agents, conjugated small molecular nanoparticles (CSMNs) prepared from D-A-typed photoactive conjugated small molecules (CSMs) have greatly mediated this deadlock by their high photostability, distinct chemical structure, tunable absorption, intrinsic multifunctionality, and favorable biocompatibility, which endows CSMNs with more possibilities in biological applications. This review aims to introduce the recent progress of CSMNs for NIR imaging, therapy, and synergistic PTs with a comprehensive summary of their molecular structures, structure types, and optical properties. Moreover, the working principles of CSMNs are illustrated from photophysical and photochemical mechanisms and light-tissue interactions. In addition, molecular engineering and nanomodulation approaches of CSMs are discussed, with an emphasis on strategies for improving performances and extending absorption and emission wavelengths to the NIR range. Furthermore, the in vivo investigation of CSMNs is illustrated with solid examples from imaging in different scenarios, therapy in 2 modes, and synergistic PTs in combinational functionalities. This review concludes with a brief conclusion, current challenges, and future outlook of CSMNs.

The Photodynamic Agent Designed by Involvement of Hydrogen Atom Transfer for Enhancing Photodynamic Therapy

Although Type-I photodynamic therapy has attracted increasingly growing interest due to its reduced dependence on oxygen, the design of effective Type-I photosensitizers remains a challenge. In this work, we report a design strategy for Type-I photosensitizers by the involvement of hydrogen atom transfer (HAT). As a proof of concept, a HAT-involved Type-I PS, which simultaneously generates superoxide and carbon-centered radicals under light-irradiation, was synthesized. This photosensitizer is comprised of a fluorene-substituted BODIPY unit as an electron acceptor covalently linked with a triphenylamine moiety as an electron donor. Under light-irradiation, photo-induced intramolecular electron transfer occurs to generate the BODIPY anion radical and triphenylamine cation radical. The former transfers electrons to oxygen to generate O2 -⋅, while the latter loses a proton to produce a benzyl carbon-centered radical which is well characterized. The resulting carbon-centered radicals efficiently oxidize NADH by HAT reaction. This photosensitizer demonstrates remarkable photocytotoxicity even under hypoxic conditions, along with outstanding in vivo antitumor efficacy in mouse models bearing HeLa tumors. This work offers a novel strategy for the design of Type-I photosensitizers by involvement of HAT.

Hydrogen Sulfide (H2S) Activatable Photodynamic Therapy Against Colon Cancer by Tunable FRET Effect

Developing activatable photodynamic agents is becoming a promising mode for realizing selective photodynamic therapy (PDT) in cancer treatment. However, till now only a few H2S-activatable photodynamic agents have been involved in this field. Here, we fabricated H2S-activatable nano-assemblies (P@TPPCY) for the treatment of colon cancer containing high concentration H2S. The H2S-activatable photosensitizer (TPPCY) was synthesized by covalent conjugation between tetraphenylporphyrin (TPP) and heptamethine cyanine (Cy7), and then TPPCY was encapsulated by an amphiphilic polymer DSPE-mPEG to form P@TPPCY nano-assemblies. We demonstrated that the photosensitizing effect of TPP was efficiently quenched by Cy7 with strong absorption in the NIR region via fluorescence resonance energy transfer (FRET) effect. Interestingly, the FRET effect between Cy7 and TPP was attenuated by the decrease of absorption of Cy7 in the NIR region after the Cy7 reacted with H2S, and then the photosensitizing effect of TPP in P@TPPCY was activated. Strikingly, the P@TPPCY showed efficient H2S-activatable photodynamic therapy (PDT) in vitro against HCT116 cells (human colon carcinoma cell line), thus this work provides a new method for realizing accurate treatment of colon cancer in virtue of high H2S concentration microenvironment.

Phthalocyanine aggregates as semiconductor-like photocatalysts for hypoxic-tumor photodynamic immunotherapy

Photodynamic immunotherapy (PIT) has emerged as a promising approach for efficient eradication of primary tumors and inhibition of tumor metastasis. However, most of photosensitizers (PSs) for PIT exhibit notable oxygen dependence. Herein, a concept emphasizing on transition from molecular PSs into semiconductor-like photocatalysts is proposed, which converts the PSs from type II photoreaction to efficient type I photoreaction. Detailed mechanism studies reveal that the nanostructured phthalocyanine aggregate (NanoNMe) generates radical ion pairs through a photoinduced symmetry breaking charge separation process, achieving charge separation through a self-substrate approach and leading to exceptional photocatalytic charge transfer activity. Additionally, a reformed phthalocyanine aggregate (NanoNMO) is fabricated to improve the stability in physiological environments. NanoNMO showcases significant photocytotoxicities under both normoxic and hypoxic conditions and exhibits remarkable tumor targeting ability. Notably, the NanoNMO-based photodynamic therapy and PD-1 checkpoint inhibitor-based immunotherapy synergistically triggers the infiltration of cytotoxic T lymphocytes into the tumor sites of female mice, leading to the effective inhibition of breast tumor growth.

Advancing Two-Photon Photodynamic Therapy Over NIR-II Excitable Conjugated Microporous Polymer with NIR-I Emission

The availability of second near-infrared (NIR-II) excitable two-photon photosensitizers with NIR-I emission for efficient photodynamic therapy (PDT) is limited by challenges in molecular design. In this study, a NIR-II light-excitable two-photon conjugated microporous polymer (Tph-Dbd) with emission in the NIR-I region is developed. The large conjugated system and delocalized electronic structures endow Tph-Dbd with a large two-photon absorption cross-section under NIR-II light excitation. Moreover, the efficient electron acceptor and donor units within the π-conjugated backbones result in NIR-I emission for high signal-to-background ratio imaging, as well as separated highest occupied molecular orbital and lowest unoccupied molecular orbital distributions for excellent singlet oxygen generation ability. The excellent NIR-II excitable two-photon absorption activity, NIR-I emission, good biocompatibility, and high photostability allow Tph-Dbd to be used for efficient in vitro fluorescence imaging guided PDT. Moreover, the impressive photothermal effect of Tph-Dbd can overcome the limitations of PDT in the treatment of hypoxic tumors. This study highlights a strategy for designing NIR-II excitable two-photon photosensitizers for advanced PDT.

Tumor microenvironment-modulated nanoparticles with cascade energy transfer as internal light sources for photodynamic therapy of deep-seated tumors

Photodynamic therapy (PDT) is an appealing modality for cancer treatments. However, the limited tissue penetration depth of external-excitation light makes PDT impossible in treating deep-seated tumors. Meanwhile, tumor hypoxia and intracellular reductive microenvironment restrain the generation of reactive oxygen species (ROS). To overcome these limitations, a tumor-targeted self-illuminating supramolecular nanoparticle T-NPCe6-L-N is proposed by integrating photosensitizer Ce6 with luminol and nitric oxide (NO) for chemiluminescence resonance energy transfer (CRET)-activated PDT. The high H2O2 level in tumor can trigger chemiluminescence of luminol to realize CRET-activated PDT without exposure of external light. Meanwhile, the released NO significantly relieves tumor hypoxia via vascular normalization and reduces intracellular reductive GSH level, further enhancing ROS abundance. Importantly, due to the different ROS levels between cancer cells and normal cells, T-NPCe6-L-N can selectively trigger PDT in cancer cells while sparing normal cells, which ensured low side effect. The combination of CRET-based photosensitizer-activation and tumor microenvironment modulation overcomes the innate challenges of conventional PDT, demonstrating efficient inhibition of orthotopic and metastatic tumors on mice. It also provoked potent immunogenic cell death to ensure long-term suppression effects. The proof-of-concept research proved as a new strategy to solve the dilemma of PDT in treatment of deep-seated tumors.

Unravelling the modes of phototoxicity of NIR absorbing chlorophyll derivative in cancer cells under normoxic and hypoxic conditions

The efficacy of photodynamic treatment (PDT) against deep-seated tumor is hindered by low penetration depth of light as well as hypoxic conditions which prevails in tumor. To overcome this limitation, Near-infrared (NIR) absorbing photosensitizers have been investigated actively. In the present study we evaluated the PDT efficacy of an NIR absorbing chlorophyll derivative 'Cycloimide Purpurin-18 (CIPp-18)' in Human Breast carcinoma (MCF-7) and cervical adenocarcinoma (Hela) cells under normoxic and hypoxic conditions. PDT with CIPp-18 (2.0 µM, 3 h) and NIR light (700 ± 25 nm, 0.36-1.4 J /cm2) induced potent phototoxicity in both the cell lines. Under hypoxic conditions, PDT induced ~ 32% and 42% phototoxicity at LD50 and LD70 light dose, respectively, which corresponds to phototoxic dose under normoxia. CIPp-18 in neat buffer (pH 7.4) showed generation of singlet oxygen (1O2) as well as superoxide (O2·-) radicals. Studies on ROS generation in cells using fluorescence probes and the effect of mechanistic probes of 1O2 (Sodium Azide, Histidine, D2O) and free radicals (DMSO, Mannitol, Cyanocobalamin, SOD-PEG) on phototoxicity show that 1O2 plays major role in phototoxicity under normoxia. Whereas, under hypoxic conditions, PDT led to no significant generation of ROS and phototoxicity remained unaffected by cyanocobalamin, a quencher of O2·-. Moreover, CIPp-18 showed localization in cell membrane and PDT led to more pronounced loss of membrane permeability in cells under hypoxia than for normoxia. These results demonstrate that CIPp-18 is suitable for PDT of cancer cells under hypoxia and also suggest that phototoxicity under hypoxia is mediated via ROS-independent contact-dependent mechanism.

Recent advances of lipid droplet-targeted AIE-active materials for imaging, diagnosis and therapy

Lipid droplets (LDs) are cellular organelles specialized in the storage and regulating the release of lipids critical for energy metabolism. As investigation on LDs deepens, the complex biological functions of LDs are revealed and their relationships with various diseases such as atherosclerosis, fatty liver, obesity, and cancer are uncovered. Fluorescence-based techniques with simple operations, visible results and high non-invasiveness are ideal tools for investigating LD-related biological processes and diseases. Materials with aggregation-induced emission (AIE) characteristics have emerged as promising candidates for investigating LDs due to their high signal-to-noise ratio (S/N), strong photostability, and large Stokes shift. This review discusses the principles and advantages of LD-targeting AIE probes for imaging LDs, diagnosis of LD-associated diseases including atherosclerotic plaques, liver diseases, acute kidney diseases and cancer, therapies with LD-targeting AIE-active photosensitizers and other relevant fields in the past five years. Through typical examples, we illustrate the status of investigating LD-related imaging, diagnosis of diseases and therapy with AIE materials. This review is expected to attract attentions from scientists with different research backgrounds and contribute to the further development of LD-targeting AIE materials.

Theranostic dye entrapped in an optimized blended-polymer matrix for effective photodynamic inactivation of diseased cells

Despite the wide range of treatment options available for cancer therapy, including chemotherapy, radiation therapy, and surgical procedures, each of these treatments has a different side-effect profile and leaves the patient with no option but to choose. Due to their insensitivity and nonspecificity, conventional treatments damage normal cells together with cancer cells. In recent years, a significant amount of attention has been focused on photodynamic therapy (PDT) as a treatment for cancer and drug-resistant microbes. An activated photosensitizer is used as a part of the procedure along with oxygen molecules and a specific wavelength of light belonging to the visible or NIR spectral zone. A light-sensitive laser dye, rhodamine 6G (R6G), was used in the present study as a photosensitizer, taking a challenge to improve the aqueous solubility and ROS quantum yield using optimum concentration (160 mg/ml) of chitosan-alginate (Cs-Alg) blended polymeric nanoformulations. As evidenced by steady-state spectrophotometric and fluorometric measurements, ROS quantum yield increases three-fold over aqueous solution along with solubility gaining that was validated by PDT experiment using human epithelial carcinoma (KB) cell line. Phantom optical imaging was taken using the IVIS imaging system to establish the formulations as a fluorescence-based optical contrast agent, and zebrafish embryos were used to establish their safe in vivo use. The release profile of R6G was fitted using kinetic models, which followed the Non-Fickian kinetic profile. In conclusion, we recommend the formulations as a potential theranostic agent that will aid in PDT-based therapy in conjunction with optical imaging-based diagnosis.